CORDIS · 303580 · FP7
BIOMEDMICROFLUIDICS Modelling and Optimization of Microfluidic Devices for Biomedical Applications
Coordinator: ZILINSKA UNIVERZITA V ZILINE (SK)
Circulating tumor cells (CTCs) are isolated tumor cells disseminated from the site of disease in metastatic or primary cancers, including breast, prostate, and lung cancer. CTCs can be identified and counted in the peripheral blood of patients. The biological analysis of CTCs using lab-on-chip technologies effectively diagnose the disease, determine personalized therapies, and adjust treatments in real time. This significantly increases the survival chance of the patients. Because of their rare occurrence, a few CTCs per 1 mL of blood, the CTCs must be isolated from the blood sample. Recent d…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €100k awarded to the consortium. The project runs over approximately 4 years from 2012-04-01 to 2016-03-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from SK
see all →- FunGlass — Centre for functional and surface-functionalized glasses739566 · H2020 · €15.0M
- LignoSilva — Upgrade of the Centre of Excellence LignoSilva101059552 · HORIZON · €14.7M
- lorAI — Low Resource Artificial Intelligence101136646 · HORIZON · €14.0M
- RURALITIES — Climate smart, ecosystem-enhancing and knowledge-based rural expertise and training centres101060876 · HORIZON · €4.4M
- SASPRO 2 — Slovak Academic and Scientific PROgramme for experienced researchers945478 · H2020 · €4.3M
- REDIRNET — Emergency Responder Data Interoperability Network607768 · FP7 · €3.5M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the MC-CIG funding scheme.
- What is the EU contribution?
- The European Commission contributes €100k toward a total project budget of €100k.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by ZILINSKA UNIVERZITA V ZILINE (SK).
- What is the project timeline?
- The project runs from 2012-04-01 to 2016-03-31 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 303580.